

		/ 0 4		•	7		Sheet	_1_ of _	9
Fo	Form PTO-1449 NON 2 & 2000 DEFERTMENT OF COMMERCE			ATTY. DOCKET NO. SERIAL NO.					
OFFI		0-1449 NOV 2 L MAN	ATENT AND TRA	ADEMARK	2836-E 09/699,923				
	INFOR	MATION DISCEO	ダ SURE CI⁻	TATION	APPLICANT				
	INFOR	RIVIATION DISCLO	SUNE OI	IATION	David H. Lynch e	t al.			
					FILING DATE GROUP 1644				
		(Use several sheets i	f necessary	<i>)</i>	October 30, 200	0		t assigne	d
U.S. PATENT DOCUMENTS									
EXAMINER		DOCUMENT NUMBER	DATE		NAME	CLAS	S SUBCLA		G DATE ROPRIATE
pG		4,745,099	05/17/88	Akamatsu et al.					
1		5,013,824 05/07/91 Abrams e		Abrams et	al.				-
		5,057,420	10/15/91	Massey, Jos	seph M.	_			•
		5,061,620	10/29/91	Tsukamoto	et al.				
		5,114,710 05/19/92 Takaku et al.		al.	_				
		5,116,964	5/26/92	Capon et al.					
		5,185,438	02/09/93	Lemischka, Ihor R.		_			
		5,192,553	03/9/93	Boyse et al.		_			
		5,199,942	04/6/93	Gillis, Stev	ren				
		5,270,458	12/14/93	Lemischka	, Ihor R.				
			F	OREIGN PA	TENT DOCUMENTS				
		DOCUMENT NUMBER	DATE		COUNTRY	CLAS	S SUBCLA	ASS TRAN	ISLATION NO
		WO 92/18615	10/29/92	PCT					
		WO 93/08268	04/29/93	PCT					
		2,163,105	05/18/94	CA					
		0 627 487 A2	05/19/94	EP					
		OTHER D	OCUMENTS	(Including A	uthor, Title, Date, Pertine	nt Page.	s, Etc.)		
		Stanley, E. R. et Growth Factor,"	al., "CSF-	1-A Mononi	uclear Phagocyte Line	eage-S ₁	pecific He	mopoieti	С
	n	Y. Yarden and A 57:443-478, 198		"Growth Fac	ctor Receptor Tyrosin	e Kina	ses," Ann.	Rev. Bio	ochem.
EX	EXAMINER DATE CONSIDERED								

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form P1	TO-1449 .∪.Ş.	OF COMMERCE	ATTY. DOCKET NO. SERIAL NO.			*	
OFFICE	HOV 2 4	ATEN AND TRA		2836-E 09/699,923			99,923
INFO	RMATION DISCLO	SURF CI	TATION	APPLICANT			
1141 0	THO TO DIGGE	00112 01	.,	David H. Lynch et	al.		
				FILING DATE	ŀ	GROUP 164	
	(Use several sheets i	f necessary	<u>,)</u>	October 30, 200	0	Not as	ssigned
			U.S. PATEN	IT DOCUMENTS			
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
po	5,283,354	02/01/94	Lemischka,	Ihor R.			
	5,326,558 07/05/94 Turner		Turner et al		-		
	5,367,057	11/22/94	Lemischka,	Ihor R.			
	5,397,706	03/14/95	Correa et al.		-		
	5,399,493	03/21/95	Emerson et	al.			
	5,437,994	08/01/95	Emerson et	et al.			
	5,453,357	09/26/95	Hogan, Brig	gid L. M.			
5,459,069 10/17/95 1		Palsson et a	1.				
	5,525,708	06/11/96	Nocka et al.	•			
	5,548,065	08/20/96	Lemischka, Ihor R.				
	5,554,512	09/10/96	Lyman et al	1.	<		
	-	F	OREIGN PAT	ENT DOCUMENTS			
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	WO 94/26891	11/24/94	PCT				
	WO 94/28391	12/08/94	PCT		_		-
	WO 95/00554 01/05/95 PCT		PCT				
OTHER DOCUMENTS (Including Author,			thor, Title, Date, Pertiner	t Pages,	Etc.)		
	J. G. Flanagan and P. Leder, "The kit Ligand: A Cell Surface Molecule Altered in Steel						in Steel
	Mutant Fibrobla						
h	D. Cadena and C	G. Gill, "Re	ceptor tyrosi	ine kinases," FASEB	6:2332	-2337, 1992.	
EXAMINE	PHILLIP GA MORE	- 6/2	2/01 -	DATE CONSIDERED			
*EXAMINE			,	is in conformance with MP	EP 609;	Draw line thro	ugh citation if
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form P	TO-1449 NOV 2 L 2000	DEPARTMENT OF ATERIT AND TR	OF COMMERCE ADEMARK	ATTY. DOCKET NO. SERIAL NO. 09/699,923				
INFO	RMATION DIBONE	SURE CI	TATION	David H. Lynch et al.				
	/XI		. 1	FILING DATE		OUP (C	47	,
	(Use several sheets i	·	October 30, 200	00	Not .	Assigne	a	
 -			U.S. PATEN	NT DOCUMENTS	<u> </u>	T	·	
EXAMINER	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING I	
N	5,843,423	12/01/98	Lyman et al	1.				
W	5,627,025	05/06/97	Steinman et	t al.				
W	5,635,388	06/03/97	Bennett et a	ıl.				
			1					
				4 - 4				
		F	OREIGN PAT	ENT DOCUMENTS	1		Т	
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSL YES	ATION NO
M	WO 93/20186	10/14/93	PCT					_
	0 563 485 A1	03/30/92	EP					
	WO 96/00779	01/11/96	PCT					
	OTHER DO	CUMENTS	(Including Au	thor, Title, Date, Pertiner	nt Pages, E	tc.)		
		Matthews, W. et al., "A Receptor Tyrosine Kinase Specific to Hematopoietic Stem and Progenitor Cell-Enriched Populations," <i>Cell</i> 65:1143-1152, 1991.						
	tyrosine kinase g	Lyman, S. D. et al., "Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene," <i>Oncogene</i> 8:815-822, 1993.						
M	Rosnet, O. et al., Kinase Gene," C			osomal Localization of 191.	of a Nove	l FMS-like	e Tyrosii	ne
EXAMINE	PHILLIPG	<i>ገ</i>	- (Szala)	DATE CONSIDERED				
*EXAMINE	R: Initial if citation conside	red, whether	or not citation i	s in conformance with MP	EP 609; D	raw line thro	ugh citatio	n if
not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-14402 NOV 2 U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.					
PATENT AND TRADEMARK	2836-E	09/699,923					
OFFICE		, i					
INFORMATION DIOCHOCUPE CITATION	APPLICANT						
INFORMATION DISCLOSURE CITATION	David H. Lynch et al.						
	FILING DATE	GROUP 1644					
(Complemental Cheet)	October 30, 2000	Not assigned					
(Supplemental Sheet)	October 30, 2000	Tiot assigned					
OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent Page	s, Etc.)					
Lyman, Stewart D. et al., "Molecular Cl	loning of a Ligand for the f	lt3/flk-2 Tyrosine Kinase					
Receptor: A Proliferative Factor for Pri	mitive Hematopoietic Cells	s," Cell 75:1157-1167,					
1993.							
Maroc, N. et al., "Biochemical character							
the FLT3/FLK2 receptor tyrosine kinase	e," Oncogene 8:909-918, 19	993.					
	remain C CLT2: II.	At. Ilraming of					
Birg, F. et al., "Expression of the FMS/							
the Myeloid and Lymphoid Lineages,"	Blood 80 (10):2584-2593, 1	1992.					
Devil M. et al. (Mitagonia Cignalling a	and Substrate Specificity of	the Ell-2/Elt3 Decentor					
Dosil, M. et al, "Mitogenic Signalling a	nd Substrate Specificity of	topoietic Cells " Mol. And					
Tyrosine Kinase in Fibroblasts and Interleukin 3-Dependent Hematopoietic Cells," M							
Cell. Biol. 13(10):6572-6585 1993. Hannum, C. et al., "Ligand for FLT3/FLK2 receptor tyrosine kinase regulates							
haematopoietic stem cells and is encode							
maematopoietic stem cens and is cheode	d by variant KivAs, Traini	2 300.043 0 10, 133 1.					
Broxmeyer, H. E. et al., "Commentary:	A Rapid Proliferation Ass.	av for Unknown Co-					
Stimulating Factors in Cord Blood Plass	ma Possibly Involved in En	hancement of In Vitro					
Expansion and Replating Capacity of H	uman Hematopoietic Stem	Progenitor Cells." Blood					
Cells 20:492-497, 1994.							
de Vries, P. et al., "The Effect of the FL	T3 Ligand On Purified Mu	rine Pluripotent					
Hematopoietic Stem Cells," J. of Cell. I	Biochem. Suppl. 18b:177, al	bstract #H110, 1994.					
Rossner, M. T. et al., "Fms-like Tyrosin	ne Kinase 3 Catalytic Doma	in Can Transduce a					
Proliferative Signal in FDC-P1 Cells Th	nat is Qualitatively Similar	to the Signal Delivered by					
c-Fms¹," Cell Growth & Differentiation							
Small, D. et al., "STK-1, the human hor	nolog of Flk-2/Flt-3, is sele	ectively expressed in					
CD34 ⁺ human bone marrow cells and is	involved in the proliferation	on of early progenitor/stem					
cells," Proc. Natl. Acad. Sci. USA 91:45							
Zeigler, F. C. et al., "Cellular and Mole	cular Characterization of th	e Role of the FLK-2/FLT-					
3 Receptor Tyrosine Kinase in Hemator	poietic Stem Cells," Blood	84(8):2422-2430, 1994.					
de Vries, P. et al., "The Role of FLT3 L	igand in Early Murine Hen	natopoiesis," Blood 84(10)					
Suppl. 1:279a, abstract #1100, 1994.	14						
Total Park Title Co. 1 Co. 1 1	1 Promoti 10 M in	- Planin stant					
de Vries, P. et al., "The Effects of Soluble FLT3 Ligand On Murine Pluripotent Hematopoietic Stem Cells," Experimental Hematology 22(8):724, abstract #174, 199							
Hematopoietic Stem Cells," Experiment	tal Hematology 22(8):124,	abstract #1/4, 1994.					
Stewart, F. M. et al., "Post-5-Fluorourae	cil Human Marrow. Stem (Cell Characteristics and					
Renewal Properties After Autologous N							
1993.	ranow Transplantation, B	1004 01(7).2203 2207,					
EYAMINER	DATE CONSIDERED						
Pully Ginge 6/20/02							
	is in conformance with MDED 600	9: Draw line through citation if					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form P	TO-144	NOV 2 1 2000 PARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.				
OFFICE		NOV 2 4 200 ATEST AND TRADEMARK	2836-E	09/699,923				
INEC		ION BROCK SURE CITATION	APPLICANT	<u></u>				
IIVIC		ION DISSECTION	David H. Lynch					
				GROUP (644				
	((Supplemental Sheet)	October 30, 2000	Not assigned				
		OTHER DOCUMENTS (Including Aut						
Α.		Bernhard, H. et al., "Generation of Immunostimulatory Dendritic Cells from Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood," <i>Cancer Res</i> .						
pu		<u> </u>	one Marrow and Peripheral	Blood," Cancer Res.				
1		55:1099-1104, 1995. Chatterjee, M. et al., "Idiotypic antibody immunotherapy of cancer," <i>Cancer Immunol</i> .						
		munotherap. 38:75-82. 1994.	immunomerapy of cancer,	Cancer Immunot.				
	Во	oon, T., "Toward a Genetic Analysis o	of Tumor Rejection Antigen	s," Adv. Cancer Res.				
		3:177-211, 1992.	,					
	M	cBride, G., "New Molecule Under Stu	idy: Flt3 Ligand May Mob	ilize Dendritic Cells," J.				
	No	at'l Cancer Inst. 89(17):1257, 1997.						
	D	alam duan D. et al. "Developmental Det	thursus of Dandwitis Calls in	Viva Distinct Eurotion				
	Dh	ilendran, B. et al., "Developmental Pat nenotype, and Localization of Dendrition	c Cell Subsets in FI T3 I ig	and Treated Mice " I				
}		nmunol. 159(5):2222-2231, 1997.	e cen subsets in 1 L13 Lig	und-freated whee, J.				
		nurin, M. et al., "FLT3 Ligand Induces	the Generation of Function	ally Active Dendritic				
		ells in Mice," Cell. Immunol. 179(2):17						
		nen, K. et al., "Antitumor Activity and						
	M	urine Breast Cancer Model," Cancer F	Res. 57(16):3511-3516, 199	7.				
		11.11 . 1 "G.O.1	.: .: .:					
		robl, H. et al., "flt3 Ligand in Coopera otentiates In Vitro Development of Lan						
.		ell Dendritic Cell Cluster Formation U						
	1	134, 1997.	nder Seram-1 ree Condition	is, <i>Dioou</i> , 70(7).1123				
		an, T. et al., "Chronic Expression of M	Aurine flt3 Ligand in Mice l	Results in Increased				
		rculating White Blood Cell Levels and						
		olenic Fibrosis," Blood 90(1):76-84, 19						
		ynch, D. et al., "Flt3 ligand induces tur		or immune responses in				
	vi	vo," Nature Med. 3(6):625-631, 1997.						
	So	unders, D. et al., "Dendritic Cell Deve	alonment in Culture from T	hymic Precursor Cells in				
the Absence of Granulocyte/Macrophage Colony-stimulating Factor," <i>J. Exp. Med.</i> 184:2185-2196, 1996.								
Maraskovsky, E. et al., "Dramatic Increase in the Numbers of Functionally Mature De								
	Cells in Flt3 Ligand-treated Mice: Multiple Dendritic Cell Subpopulations Identified," J. Exp. Med. 184:1953-1962, 1996.							
N	E. Sprecher and Y. Becker, "Role of Langerhans cells and other dendritic cells in viral diseases," <i>Arch. Virol.</i> 132:1-28, 1993.							
EXAMINE	7		DATE CONSIDERED					
•	Pi	HILLIP GAMBEL 6/26/01						
*EXAMINE		if citation considered, whether or not citation is	s in conformance with MPEP 600	Draw line through citation if				

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-	1449 NOV 2 2000 U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.			
OFFICE	NOV 2 4 2000 SATENT AND TRADEMARK	2836-E	09/699,923			
INICODA	MATION DISSELLOSURE CITATION	APPLICANT	<u> </u>			
INFORIV	MATION AND SECTION	David H. Lynch et al.				
		FILING DATE	GROUP 1644			
·	(Supplemental Sheet)	October 30, 2000	Not assigned			
	OTHER DOCUMENTS (Including Aut					
m	Broxmeyer, H. et al., "Flt3 ligand stimustem/progenitor cells," Exp. Hematol. 2.	-	th of myeloid			
	A. Porgador and E. Gilboa, "Bone Marrestricted Peptide are Potent Inducers of 260, 1995.	Cytotoxic T Lymphocytes	," J. Exp. Med. 182:255-			
	Hudak, S. et al., "FLT3/FLK2 Ligand Pr Expansion Of Colony-Forming Cells Ar 85(10):2747-2755, 1995.	nd Spleen Colony-Forming	Units," Blood			
	Muench, M. et al., "FLK-2/FLT-3 Ligar Progenitors Isolated From Human Fetal	nd Regulates The Growth C Liver," <i>Blood 85(4)</i> :963-97	of Early Myeloid 72, 1995.			
	Steinman, R., "The Dendritic Cell System and Its Role in Immunogenicity," Annu. Rev. Immunol. 9:271-296, 1991.					
	Macatonia, S. et al., "Primary proliferativitro by human dendritic cells," <i>Immuno</i>		ponses to HIV induced in			
	Pancholi, P. et al., "Dendritic Cells Efficiently Immunoselect Mycobacterial-Reactive T Cells In Human Blood, Including Clonable Antigen-Reactive Precursors," <i>Immunology</i> 76:217-224, 1992.					
	Inaba, K. et al., "Dendritic Cells Pulsed Specific, MHC-Restricted T Cells In Sit					
	Bujdoso, R. et al., "Afferent Lymph Der Presentation In Vivo," Intern. Rev. Immu		Antigen Capture And			
	Jaffe, R., "Review Of Human Dendritic Cells: Isolation And Culture From Precursors," Pediatric Pathology 13:821-837, 1993.					
	Bermstein, I. et al., "Isolation Of Human 1994.	n Hematopoietic Stem Cells	s," Blood Cells 20:15-24,			
	Young, J. et al., "Identification Of Dend Human CD34 ⁺ Bone Marrow Progenitor Pure Dendritic Cell Colonies In The Pre Stimulating Factor And Tumor Necrosis	rs That Are Expanded By C sence Of Granulocyte/Mac s Factor α ," <i>J. Exp. Med. 18</i>	C-Kit Ligand And Yield rophage Colony- 2:1111-1120, 1995.			
m	Inaba, K. et al., "Dendritic Cell Progenit Calmette-Guerin Organisms, And Sensit Exp. Med. 178:479-488, 1993.	tize Mice To Mycobacteria				
EXAMINER	PHILLIP GAMBER 6/20/or	DATE CONSIDERED				
	nitial if citation considered, whether or not citation is	s in conformance with MPEP 609	; Draw line through citation if			
	nance and not considered. Include copy of this forn					

Form P	TO-1449 U.S. SEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.						
	介加 PAT性NT AND TRADEMARK	2836-E	09/699,923						
INFO	PRMATION DISCLOSURE CITATION	APPLICANT							
		David H. Lynch et al.							
•	(Supplemental Sheet)	October 30, 2000	GROUP 1647 Not assigned						
	OTHER DOCUMENTS (Including Aut	thor, Title, Date, Pertinent Pages	s, Etc.)						
	Papayannopoulo et al., "In Vivo Effects	Papayannopoulo et al., "In Vivo Effects of Flt3/Flk2 Ligand on Mobilization of							
M	Hematopoietic Progenitors in Primates a Granulocyte Colony-Stimulating Factor								
	Lotem, J. and Sachs, L., "Control of In Leukemia 2(12 Suppl.):24S-37S, 1988.								
	Stewart D. Lyman et al., "Cloning of the Growth Factor for Early Hematopoietic	e Human Homologue of the Progenitor Cells," <i>Blood 83</i>	Murine flt3 Ligand: A 3(10):2795-2801, 1994.						
	D. Hanahan, "Transgenic Mice as Probe 1989.	es into Complex Systems,".	Science 246:1265-1275,						
	Romani, N. et al., "Proliferating Dendrit 180:83-93, 1994.	tic Cell Progenitors in Hum	an Blood," J. Exp. Med.						
	Winton, E. F. et al., "Recombinant Hum Causes a Marked CD34* Cell Mobilizati December 1996.	ion to Blood in Rhesus Mor	nkeys," ASH Abstract,						
	F. Sallusto and A. Lanzavecchia, "Efficient Human Dendritic Cells is Maintained by Factor Plus Interleukin 4 and Downregu 179:1109-1118, 1994.	Granulocyte/Macrophage	Colony-stimulating						
	Szabolcs, P. et al, "Expansion of Immur Progeny of Human CD34 ⁺ Bone Marrov	v Precursors Cultured with	c-kit Ligand,						
	Granulocyte-Macrophage Colony-Stimu 5861, 1995.								
	Rosnet, O. et al., "Murine Flt3, a gene e PDGFR/CSF1R family," Oncogene 6:10	641-1650, 1991.							
S. Stengelin et al., "Isolation of cDNAs for two distinct human Fc receptors by ligand cloning," <i>EMBO J. 7(4)</i> :1053-1059, 1988									
	Debets, R. and Savelkoul, H. F. J. "Cytokine antagonists and their potential therapeutic use <i>Immunol. Today 15(10)</i> :455-458, 1994.								
	Small et al., "STK-1 is Expressed in a Subpopulation of Human Bone Marrow Enriched for CD34 ⁺ Progenitor/Stem Cells and in a Number of Leukemic Cell Lines," <i>Blood 80</i> , 296a; Abstract No. 1175, 1992.								
p	Reid, D. L. et al., "Interactions Of Tumor Necrosis Factor With Granulocyte-Macrophage Colony-Stimulating Factor And Other Cytokines In The Regulation Of Dendritic Cell Growth In Vitro From Early Bipotent CD34 ⁺ Progenitors In Human Bone Marrow," J. of Immunol. 149(8):2681-2688, 1992.								
EXAMINER	PHILLIP GAMBEL 6/20/01	DATE CONSIDERED							
*EXAMINE	R: Initial if citation considered, whether or not citation is	s in conformance with MPEP 609	: Draw line through citation if						

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•	× ,				
Form P	TO-1449 RADENANS. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO.		
	PATENT AND TRADEMARK	2836-E	09/699,923		
OFFICE					
	THE PLANT BLOOM COLUMN OF THE PARTY OF THE P	APPLICANT			
INFO	PRMATION DISCLOSURE CITATION	David H. Lynch et al.			
		FILING DATE	GROUP (C YL)		
	(0 1 1 1 1)		D 14		
	(Supplemental Sheet)	October 30, 2000	Not assigned_		
	OTHER DOCUMENTS (Including Au				
, , , ,	Thomson, A. W. et al., "Microchimeris		ors and Transplantation		
MC	Tolerance," Stem Cells 13:622-639, 199	95.			
		1	1 G: /D :: 'A- :: C-11		
[Lyman, S. D. and Jacobsen, S. E. W., "c				
	Factors With Overlapping Yet Distinct	Activities," Blood 91(4): 1	101-1134, 1998.		
$H \longrightarrow$	D. D. I. et al. ((Classical acceptable)	a differentiation of conty D	call progenitors in the		
	Ray, R. J. et al., "Flt3 ligand supports the		cen progenitors in the		
	presence of IL-11 and IL-7," Manuscrip	or, February 20, 1990.			
	Chklovskaia, E. et al., "Increased Produ	ection of FLT3 Ligand in L	eukemia Patients With		
	Chemotherapy-Induced Bone Marrow S				
	Meeting of the European Haematology				
	Wodnar-Filipowicz, A. et al., "Tyrosine	kinase receptors and their	ligands in aplastic		
	anemia," Manuscript, February 20, 1996				
	unionia, inianascripi, recraary 20, 222				
	Hsu, F. et al, "Antigen-Pulsed Dendrition	Cells in the Treatment of	Patients with B-cell		
Lymphoma," Abstract # C1-314, Keystone Conference, Taos, NM, March 1995.					
	Drexhage, H. A., "A Defective Maturat				
	Diabetics," Abstract # C1-204, Keyston	ne Conference, Taos, NM, N	March 1995.		
	Fisch, P. et al., "Ex Vivo Generation of	Functionally Active Antige	n Presenting Cells From		
	Peripheral Blood CD34 ⁺ Hematopoietic	Progenitor Cells in Cancer	Patients," Abstract # C1-		
	311, Keystone Conference, Taos, NM,	March 1995.			
	Mayordomo, J. et al., "Bone Marrow-D	Perived Dendritic Cells Serv	e as Potent Adjuvants for		
	Peptide-Based Antitumor Vaccines," A	bstract # C1-213, Keystone	Conference, Taos, NM,		
	March 1995.		. T 22		
	Lenz, P. et al., "MHC Class I'/II Dendr				
	Abstract # C1-318, Keystone Conference	ce, Taos, NM, March 1995.			
	Ye, Z. et al., "Evaluation of Dendritic C	Calle in Alloganaic Marrow	Grafte "Abstract # C1-		
	130, Keystone Conference, Taos, NM,		Glaits, Abstract # C1-		
	150, Reystone Conference, 1 aos, NW,	March 1993.			
Thomson, A. W. et al., "Growth of Donor-Derived Dendritic Cells From the Bone N					
Murine Liver Allograft Recipients in Response to Granulocyte/Macrophage Colony-					
	Stimulating Factor," Abstract # C1-125				
	Whalen, R. G. et al., "DNA-Mediated I				
M	Potential Involvement of Interstitial De	-	_		
	Conference, Taos, NM, March 1995.	nume cons, mostrace " c	1 120, 110,010110		
EXAMINER	3	DATE CONSIDERED			
	PHILLIP GAMBA 6/10/2				
*EYARAIRIE	R: Initial if citation considered, whether or not citation is	is in conformance with MPEP 50	9: Draw line through citation if		
not in cor	in: Initial if citation considered, whether or not citation in formance and not considered. Include copy of this for	m with next communication to ap	plicant.		

Sheet	9	of	9

Form P	TO-1	420	U.S: P	RTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.	
OFFICE		V V	ADEMARKATENT	T AND TRADEMARK	2836-E	09/699,923	
1				DE CITATION	APPLICANT		
INFC)KM/	AHON D	ISCLOSU	RE CITATION	David H. Lynch et al.	·	
					FILING DATE	GROUP	
		(Supple	emental She	et)	October 30, 2000	Not assigned	
· · · · · ·					thor, Title, Date, Pertinent Page		
	Alters, S. et al., "Characterization and C						
N		Antigen	Presentation	, Abstract # C1-30	2, Keystone Conference, Ta	aos, NM, March 1995.	
			-				
		,					
		·					
 -							
				-			
EXAMINE	L R	<u> </u>			DATE CONSIDERED		
	ĵ	PHIL CUP	Gamas	2 6/2/ov			
*EXAMINE	*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						